ACAD Acadia Pharmaceuticals Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: ACAD
  4. Earnings
?
Relative Growth: Rel. Growth: 53
Relative Strength: Rel. Strength: 58
Relative Valuation: Rel. Valuation: 76
Relative Profitability: Rel. Profitability: 92

EPS in 2026 (TTM): $2.23

Last Report Period Date: Mar 31, 2026

Based on the company's latest reports for March 2026, the current EPS (TTM) is $2.23. Acadia Pharmaceuticals's earnings per share in 2025 came in at $2.32, marking an increase from $1.37 in 2024. For the quarterly period ending on Mar 31, 2026, ACAD's earnings per share was $0.02.

ACAD earnings history

Historical annual and quarterly earnings per share (EPS) data for Acadia Pharmaceuticals
EPS (TTM)
$2.23
EPS Growth YoY (Quarterly)
-81.8%
EPS (Quarterly)
$0.02
EPS Growth (Quarterly)
-98.8%

Acadia Pharmaceuticals had an yealy EPS of $2.32, marking an increase of 69.3% from $1.37 recorded in 2024. The quarterly EPS for the period ending Mar 31, 2026, was $0.02, marking a 81.8% decline compared to the same quarter last year. ACAD's TTM EPS is $2.23 as of March 2026. Acadia Pharmaceuticals's EPS for 2024 was $1.37, a 470.3% rise from 2023.

ACAD earnings chart

ACAD EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-81.8%
EPS growth YoY
69.3%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Acadia Pharmaceuticals has recorded a decrease in earnings per share of 81.8% over the past 12 months (YoY, quarterly).

ACAD Earnings Waterfall

Breakdown of revenue, profit and net income for Acadia Pharmaceuticals

ACAD Earnings vs Peers

What are the earnings of ACAD compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
ACAD Acadia Pharmaceuticals Inc 11.65 69.3% N/A N/A
BMY Bristol Myers Squibb Co 16.28 178.7% 5.3% N/A
PFE Pfizer Inc 18.56 -3.5% -37.4% -3.7%
JNJ Johnson & Johnson 30.13 90.6% 17.7% 14.8%
LLY ELI LILLY & Co 43.06 95.6% 49.2% 27.5%
VNDA Vanda Pharmaceuticals Inc N/A -1,033.3% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.